語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Bioequivalence requirements in vario...
~
Kanfer, Isadore.
Bioequivalence requirements in various global jurisdictions
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Bioequivalence requirements in various global jurisdictions/ edited by Isadore Kanfer.
其他作者:
Kanfer, Isadore.
出版者:
Cham :Springer International Publishing : : 2017.,
面頁冊數:
x, 345 p. :ill., digital ; : 24 cm.;
Contained By:
Springer eBooks
標題:
Drugs - Therapeutic equivalency. -
電子資源:
http://dx.doi.org/10.1007/978-3-319-68078-1
ISBN:
9783319680781
Bioequivalence requirements in various global jurisdictions
Bioequivalence requirements in various global jurisdictions
[electronic resource] /edited by Isadore Kanfer. - Cham :Springer International Publishing :2017. - x, 345 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v.282210-7371 ;. - AAPS advances in the pharmaceutical sciences series ;3..
Brazil -- Canada -- China -- The European Union -- India -- Bioequivalence Studies in Japan -- Middle East and North Africa (MENA) Bioequivalence Requirements -- Russia -- South Africa -- The United States of America -- World Health Organization (WHO)
Although the Bioequivalence (BE) requirements in many global jurisdictions have much in common, differences in certain approaches and requirements such as definitions and terms, choice of comparator (reference) product, acceptance criteria, fasted and fed studies, single and multi-dose studies, biowaivers and products not intended for absorption into the systemic circulation (locally acting medicines and dosage forms), amongst others, provide food for thought that standardisation should be a high priority objective in order to result in a harmonized international process for the market approval of products using BE. An important objective of Bioequivalence Requirements in Various Global Jurisdictions is to attempt to gather the various BE requirements used in different global jurisdictions to provide a single source of relevant information. This information from, Brazil, Canada, China, European Union, India, Japan, MENA, Russia South Africa, the USA and WHO will be of value to drug manufacturers, regulatory agencies, pharmaceutical scientists and related health organizations and governments around the world in the quest to harmonize regulatory requirements for the market approval of generic products.
ISBN: 9783319680781
Standard No.: 10.1007/978-3-319-68078-1doiSubjects--Topical Terms:
778156
Drugs
--Therapeutic equivalency.
LC Class. No.: RM301.45
Dewey Class. No.: 615.1
Bioequivalence requirements in various global jurisdictions
LDR
:02513nam a2200325 a 4500
001
922323
003
DE-He213
005
20171205202306.0
006
m d
007
cr nn 008maaau
008
190624s2017 gw s 0 eng d
020
$a
9783319680781
$q
(electronic bk.)
020
$a
9783319680774
$q
(paper)
024
7
$a
10.1007/978-3-319-68078-1
$2
doi
035
$a
978-3-319-68078-1
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RM301.45
072
7
$a
TDCW
$2
bicssc
072
7
$a
MED072000
$2
bisacsh
082
0 4
$a
615.1
$2
23
090
$a
RM301.45
$b
.B615 2017
245
0 0
$a
Bioequivalence requirements in various global jurisdictions
$h
[electronic resource] /
$c
edited by Isadore Kanfer.
260
$a
Cham :
$c
2017.
$b
Springer International Publishing :
$b
Imprint: Springer,
300
$a
x, 345 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
AAPS advances in the pharmaceutical sciences series,
$x
2210-7371 ;
$v
v.28
505
0
$a
Brazil -- Canada -- China -- The European Union -- India -- Bioequivalence Studies in Japan -- Middle East and North Africa (MENA) Bioequivalence Requirements -- Russia -- South Africa -- The United States of America -- World Health Organization (WHO)
520
$a
Although the Bioequivalence (BE) requirements in many global jurisdictions have much in common, differences in certain approaches and requirements such as definitions and terms, choice of comparator (reference) product, acceptance criteria, fasted and fed studies, single and multi-dose studies, biowaivers and products not intended for absorption into the systemic circulation (locally acting medicines and dosage forms), amongst others, provide food for thought that standardisation should be a high priority objective in order to result in a harmonized international process for the market approval of products using BE. An important objective of Bioequivalence Requirements in Various Global Jurisdictions is to attempt to gather the various BE requirements used in different global jurisdictions to provide a single source of relevant information. This information from, Brazil, Canada, China, European Union, India, Japan, MENA, Russia South Africa, the USA and WHO will be of value to drug manufacturers, regulatory agencies, pharmaceutical scientists and related health organizations and governments around the world in the quest to harmonize regulatory requirements for the market approval of generic products.
650
0
$a
Drugs
$x
Therapeutic equivalency.
$3
778156
650
1 4
$a
Biomedicine.
$3
593880
650
2 4
$a
Pharmaceutical Sciences/Technology.
$3
768561
700
1
$a
Kanfer, Isadore.
$3
583395
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer eBooks
830
0
$a
AAPS advances in the pharmaceutical sciences series ;
$v
3.
$3
889162
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-68078-1
950
$a
Biomedical and Life Sciences (Springer-11642)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入